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Parallel Trade in Prescription Medicines in the European Union: 
The Age of Reason?
by
Ian S. Forrester* QC and Anthony Dawes**
“Hamlet:
Madam, how like you this play?
Queen:
The lady doth protest too much, methinks.”
William Shakespeare, Hamlet Act 3, scene 2.
Introduction
European competition law, uniquely in the world, attributes high importance, 
and uses the competition rules, to achieve market integration. In the early 
years, EC competition decisions punished manufacturers and resellers who 
contractually inhibited parallel traders. Such actions may have rewarded “free 
riders” but also helped to create consumer awareness of cross-border shopping 
opportunities. However, the case of prescription medicines is different.
Parallel trade in prescription medicines, unlike parallel trade in other products, 
is driven by discrepancies between how Member States set prices. Member States 
individually choose whether to set higher prices, which will support research 
and development (R&D), employment and the emergence of new medicines, 
or whether to set lower prices and thus reduce the pressure on national health 
budgets. Neither of these two policies is right or wrong, but they result in very 
 * Queen’s Counsel at the Scots Bar, Visiting Professor, University of Glasgow, White & Case, 
Brussels. The author is part of the team that represents GlaxoSmithKline (GSK) before the 
European Court of Justice in Syfait v. GlaxoSmithKline and Sot. Lélos kai Sia E.E. and Others 
v. GlaxoSmithKline, as well as in GlaxoSmithKline Services v. Commission, however, these are 
purely personal views.
** White & Case, Brussels. The above disclaimer applies.
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different price levels across the EU, thereby creating disparities which parallel 
traders are able to exploit. That trade, though economically irrational, is as a matter 
of Community policy, perfectly legal and highly profitable for the wholesalers.
The European pharmaceutical industry has therefore argued that since such 
price regulation distorts normal conditions of competition in the sector, the 
industry should be entitled to adopt measures reacting to – but not prohibiting 
or eliminating – parallel trade, and that such measures should not be considered 
contrary to the European Community (“EC”) competition rules1. By contrast, 
parallel traders2, the European Commission (“the Commission”) and certain 
Member States3 have maintained that the pharmaceutical industry cannot seek 
to adopt measures preventing parallel trade in prescription medicines as to 
do so would run contrary to one of the fundamental (and unique) goals of 
EC competition law. 
These issues are of great economic importance and legal interest. This 
paper will therefore review some of these controversies and show that the 
specific legal and economic context in which the European prescription 
medicines sector operates sets parallel trade in prescription medicines apart 
from parallel trade in other goods. We argue that this specific context should 
entitle pharmaceutical companies to adopt proportionate measures to react 
to such parallel trade. 
The specific and legal economic context in which parallel trade in prescription 
medicines takes place sets the sector apart from trade in other goods
Parallel trade is not needed by payers to reduce the price of prescription medicines 
Parallel trade is conventionally considered to make markets more efficient, 
which brings about lower prices for consumers and introduces inter-brand 
price competition. In the case of prescription medicines, however, there is 
1 See European Federation of Pharmaceutical Industries and Associations (‘EFPIA’), 
Competition Policy in the Pharmaceutical Sector – Article 82 EC: Can It Be Applied to Control 
Sales by Pharmaceutical Manufacturers to Wholesalers?, Research Project, November 2004, 
accessible at: http://www.efpia.eu/Content/Default.asp?PageID=559&DocID=4354. 
2 See European Association of Euro-Pharmaceutical Companies (‘EAEPC’), Understanding 
Competition in the Distribution of Pharmaceutical Products in Europe: An Analysis of the Application 
of Article 82 EC to Supply-restrictions in the Pharmaceutical Sector, September 2005, accessible at: 
http://www.eaepc.org/admin/files/eaepc_article_82_study_september_2005.pdf.
3 The Republic of Poland has intervened in both the GlaxoSmithKline Services Unlimited appeals 
(Cases C-501/06 P, GlaxoSmithKline Services Unlimited v Commission and C-513/06 P, Commission 
v GlaxoSmithKline Services Unlimited, pending) and Lelos preliminary references (Joined Cases 
C-468-478/06 Sot. Lelos kai Sia EE and Others v. GlaxoSmithKline Anonimi Emporiki Viomikhaniki 
Etairia Farmakeftikon Proionton, judgment of 16 September 2008, not yet reported).
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effectively no price competition at patient level. Patients do not “shop around” 
for the cheapest prescription medicine since the State pays all or most of the 
cost, and sets the price. So there is no intra-brand competition for prescription 
medicines as there is for sports equipment, food or washing machines. Patients 
cannot choose between prescribed medicines on the basis of price: each 
pharmacy charges the same price in accordance with national regulations. 
Most of the potential “savings” from parallel trade are therefore consumed 
by intermediaries at either the wholesale or the pharmacy level. Thus, there 
is no intra-brand price competition in the normal sense.
Parallel trade is also not needed by governmental payers to reduce the 
price of prescription medicines. They can do it directly. For example, the 
United Kingdom (“UK”) imposed unilateral profit reductions of 4.5% in 1999 
and of 7% in 2004 on all prescription medicines delivered by pharmaceutical 
companies. Germany similarly introduced price cuts on the ex-factory prices of 
prescription medicines not affected by reference pricing of 6% in 2003, of 16% 
in 2004 and of 6% in 2005. Other Member States have also imposed similar 
price cuts: for example Italy (5% in 2002, 7% in 2003, 6.8% in 2004 and over 
9% in 2006), Spain (6% in 1999/2000, 4.2% in 2004 and 2% in 2006), etc.
Some Member States have also introduced “claw back” regulations in order 
to recover part of the windfall profits earned by pharmacies and wholesalers via 
parallel trade. For example, UK intermediaries engaged in parallel imports were 
not passing on those profits to patients, who pay the same amount (zero or a 
fixed prescription fee, depending on the patient) regardless of whether or not a 
product was parallel-imported. Moreover, the UK health system was reimbursing 
pharmacies that had purchased prescription medicines from parallel traders at the 
higher “official” rate for original prescription medicines, regardless of the actual 
price pharmacies paid to wholesalers. A discount recovery scheme, the so-called 
“claw back”, was therefore established, not in order to encourage parallel trade, 
but to claw back some of the profits accruing to pharmacists and wholesalers.
Moreover, it seems that the Member States who have put in place such 
schemes would happily dispense with the alleged savings they receive from 
parallel trade. In 1999, Mr. Frank Dobson, the then UK Secretary of State for 
Health, noted that for every pound the National Health System (‘NHS’) saved 
through the claw back, £ 6 were lost by the British pharmaceutical industry, which 
was a “bad bargain” for the UK4. Equally, in 2005, the then Health Minister, 
Jane Kennedy MP, stated that the savings attributable to the claw back were less 
than 1% of the UK budget for prescription medicines5.
4 See Script No. 2428, 14 April 1999, p. 2.
5 Mrs. Kennedy stated on 6 June 2005 that savings were £60 million in England and 
Wales.
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Consequently, parallel trade of prescription medicines from one Member 
State to another does not confer on those who pay for medicines significant 
advantages. Patients and national governments are largely unaffected 
in what they expend by whether the prescription medicines they get are 
parallel-imported or not. 
The effects of parallel trade of prescription medicines on R&D
Competition in the prescription medicines sector is based around innovation 
in the development of new medicines. This should ensure that new products 
reach the market and benefit consumers6. It is only through innovation that 
pharmaceutical companies are able to discover new medicines.
A pharmaceutical company’s return on investment is highly dependent on 
a limited number of products which are increasingly costly to develop and 
which enjoy a limited period of exclusivity before patent expiry. Those costs 
were quantified in 2005 in the region of EUR 800 million per commercialised 
prescription medicine. As only one or two out of 10,000 compounds initially 
tested make it to the market, successful prescription medicines must therefore 
pay for the costs of all the other unsuccessful ones.
Moreover, due to the long lead time between the awarding of a patent for 
a compound and the grant of a marketing authorisation for the medicine7, 
coupled with substantial delays in obtaining prices or reimbursement approvals, 
or both in some countries8, the period of commercial monopoly where a 
6 Commission Communication COM(1998) 588 final of 25 November 1998 on the Single 
Market in Pharmaceuticals, pp. 3, 11, 16.
7 All medicinal products must be evaluated by the relevant competent authorities and 
approved before they may be sold. The same levels of quality, safety and efficacy must be 
demonstrated by all medicinal products and in all Member States. See Article 6 of Directive 
2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the 
Community code relating to medicinal products for human use, as amended, OJ [2001] L 311/67 
and Article 3 of Regulation (EC) No 726/2004 of the European Parliament and of the Council 
of 31 March 2004 laying down Community procedures for the authorisation and supervision 
of medicinal products for human and veterinary use and establishing a European Medicines 
Agency, OJ [2004] L 136/1.
8 In 2004, EFPIA commissioned IMS Health to produce a bi-annual study of delays 
between marketing authorization and effective patient access to new medicines in different 
EU  Member States. The resulting „Patients’ W.A.I.T. Indicator Report” (Waiting to Access 
Innovative Therapies) reveals substantial differences in patient access to new medicines across 
the European Union. The latest edition – the Patients’ W.A.I.T. Indicator Phase 8 Report 
published in November 2007 – shows that, for 18 of the 20 European countries covered in the 
report, 20 to 94% of the medicines that received a marketing authorisation between 1 January 
2003 and 31 December 2006 were still not available to patients on 30 June 2007. See http://www.
efpia.eu/content/default.asp?PageID=559&DocID=3658. 
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pharmaceutical company may effectively seek to recoup its investment on a 
product prior to the expiry of patent protection is as little as eight or nine 
years9 as when the compound goes off-patent and generic medicines come 
on to the market, there is a dramatic fall in price. Pharmaceutical companies 
launch new patented products in order to earn profit which finances today’s 
R&D in order to discover tomorrow’s medicines. According to the European 
Commission’s 2007 scorecard of worldwide corporate investment in R&D10, 
the pharmaceutical sector is now the top global investor in R&D and has the 
highest R&D intensity ratios of all sectors.
In that regard, parallel trade in prescription medicines reduces the profits 
that pharmaceuticals companies are able to invest in R&D activities. Parallel 
traders not only make no contribution to pharmaceutical innovation but they 
reduce the profits of manufacturers in high-cost countries, which, in turn, 
limits the ability of manufacturers to invest in the R&D of the future.
Parallel trade risks delaying the launch of new medicines
Before a pharmaceutical product can be put on the list for prescription by 
doctors, its price must be set by the competent public authority. The question 
arises of whether the company having decided to accept to sell in a Member 
State like Spain, Greece or Italy at a certain price must also accept to supply 
at the same price the needs of patients in other countries. If so, this could 
create a disincentive to launch in low-price countries
“it is entirely conceivable that, if they cannot negotiate a price increase in low-price 
Member States, dominant pharmaceutical undertakings would respond to an 
obligation to supply parallel traders within a given Member State by removing 
existing products from the market in that State, if they were able to do so, and by 
delaying the launch of new products there. Price differentials would be replaced by 
a greater fragmentation of the market, with a differing range of products available 
from State to State”11.
Certain patients in some low-priced Member States would therefore have 
limited or no access to the newest medicines, something which is neither the 
 9 So-called Supplementary Protection Certificates (“SPCs”) prolong patent duration, but 
it remains true that the overall period is short. See Council Regulation No (EEC) 1768/92, of 
18 June 1992, concerning the creation of a supplementary protection certificate for medicinal 
products, OJ [1992] L 182/1.
10 Accessible at: http://europa.eu/rapid/pressReleasesAction.do?reference=IP/07/
1448&format=HTML&aged=0&language=EN&guiLanguage=en.
11 Opinion of Advocate General Jacobs delivered on 27 October 2004 in Case C-53/03, 
Synetairismos Farmakopoion Aitolias & Akarnanias (Syfait) and Others v. GlaxoSmithKline plc 
and GlaxoSmithKline AEVE, [2005] ECR I-4609, para. 95.
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aim of the pharmaceutical industry, nor should it be that of EC competition 
law. Indeed, as the ECJ noted in Lelos,
“in the light of the Treaty objectives to protect consumers by means of undistorted 
competition and the integration of national markets, the Community rules on 
competition are also incapable of being interpreted in such a way that, in order 
to defend its own commercial interests, the only choice left for a pharmaceuticals 
company in a dominant position is not to place its medicines on the market at all 
in a Member State where the prices of those products are set at a relatively low 
level”12.
Similarly, if it were impossible for pharmaceutical companies to adopt 
proportionate measures to react to parallel trade, this might have the effect 
of exporting the pricing policies of Member States which set prices at a lower 
level and imposing them on Member States which set prices at a higher level in 
order to support R&D, employment and the emergence of new medicines.
As a result, while a pharmaceutical company is free to put on the market a 
product in a Member State on the basis of the price proposed by the Member 
State authorities, it cannot be the case that, if it has chosen to put a product 
on the market at a given price, it must then accept to supply patients across 
the EU at that same price.
Parallel trade and increased risks relating to the entry into the legitimate 
supply chain of counterfeit medicines
There have also been a number of recent controversies concerning parallel 
trade and the entry into the legitimate supply chain of counterfeit prescription 
medicines. According to the Commission, there has been a sharp increase in 
seized counterfeit medicines in recent years. Statistics report the seizure of 
2 711 410 medicinal products at EU customs borders in 2006, an increase of 
384% compared to 200513 and of 4 081 056 in 2007, a further increase of 51% 
compared to 200614.
Counterfeit medicines are commonly made in countries outside the EU. 
Sometimes they contain diluted active ingredient and sometimes they contain 
12 Judgment in Joined Cases C-468/06-478/06, para. 68.
13 Report on Community customs activities on counterfeit and piracy – results at the European 
border – 2006, accessible at: http://ec.europa.eu/taxation_customs/resources/documents/customs/
customs_controls/counterfeit_piracy/statistics/counterf_comm_2006_en.pdf 
14 Report on Community customs activities on counterfeit and piracy – results at the 
European border – 2007, accessible at: http://ec.europa.eu/taxation_customs/resources/
documents/customs/customs_controls/counterfeit_piracy/statistics2007.pdf 
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no active ingredient at all. Common targets for such fraudulent activity are 
prescription medicines for cardiovascular diseases or erectile dysfunction.  
The multiplicity of repackaging and re-boxing and re-labelling procedures 
which parallel trade involves can make it easier for fraudulent operators to 
introduce into the supply chain boxes of product which look almost identical 
to the genuine product to the unpractised eye. For example, on 24 May 
2007, the UK regulatory authority (the Medicines and Healthcare products 
Regulatory Agency or MHRA) issued four separate Drug Alerts following 
the discovery of multiple batches of counterfeit cancer, cardiovascular and 
psychiatric prescription medicines in the parallel supply chain in the UK. All 
the counterfeit tablets had been supplied in French livery and the packaging 
had been over-labelled and/or replaced for sale in the UK as parallel imported 
products15.
The risk of counterfeits entering the legitimate supply chain is an increasingly 
serious issue, so serious that the Commission, as part of the broader public 
debate on the future of pharmaceuticals in Europe, is analysing “patients’ safety 
aspects of prescription medicines in the distribution chain, including aspects 
related to parallel trade and to counterfeiting of prescription medicines”16. 
Moreover, as Enterprise Commissioner Verheugen stated on 15 January 2008, 
in response to a parliamentary question17, the first results of the Commission’s 
study show that the repackaging linked to parallel trade poses a “considerable 
risk” for the safety of the patients. He explained that “[t]he reasons for that 
are numerous e.g. there are problems with the packaging and labelling of the 
products as well as with product recalls, the complexity of the distribution 
channels and the supply.” As a result, the Commissioner announced that the 
Commission will prioritise this issue and issue a legislative proposal to tackle 
counterfeits, which is scheduled for adoption before the end 2008. 
Finally, the Commission has also recently published the results of a study 
commissioned in 2006 from Europe Economics18, which confirms that the 
“system of parallel trade in patented medicines under present legislation is 
15 For more details, see C. Stothers, “Counterfeit Pharmaceuticals Enter The Parallel 
Supply Chain” (2007) 2 Journal of Intellectual Property Law & Practice 797.
16 The Future of Pharmaceuticals for Human Use in Europe, accessible at: http://ec.europa.
eu/enterprise/pharmaceuticals/pharmacos/docs/doc2007/2007_07/consultationpaper-2007-07-19.
pdf. 
17 Oral Question for Question Time at the part-session in January 2008 pursuant to Rule 
109 of the Rules of Procedure of the European Parliament by Mairead McGuinness MEP, 
H-0980/07, accessible at: http://www.europarl.europa.eu/sides/getDoc.do?type=CRE&referen
ce=20080115&secondRef=ITEM-017&language=EN#2-245 
18 Safe Medicines through Parallel Trade, 13 May 2008, accessible at: http://ec.europa.eu/
enterprise/pharmaceuticals/pharmacos/docs/doc2008/2008_10/report13may_corr.pdf 
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damaging to patients in a number of ways”19 and that these “main adverse 
results are systemic, and not the result of failings by individual businesses or 
regulators”20. The study therefore concludes that
“the clearly preferable policy option would be to legislate to prohibit repackaging and 
re-labelling, and to ensure that the original packaging is not opened before the pack 
reaches the patient. This would result in a dramatic reduction in the level of parallel 
trade and in the loss or redeployment of some 10,000 jobs. It would however remove 
the harm to patients that results from parallel trade, improve the operation of the 
EU Single Market by making it possible for increased supplies of medicines to be 
purchased by healthcare providers in lower-income Member States, and contribute 
positively to other EU objectives including the Lisbon Strategy for a more competitive 
economy, improved environmental policy, and better regulation”21.
We submit that it is interesting to consider whether the risks to patient health 
and safety of widespread and unsupervised repackaging of prescription medicines 
are outweighed by the economic advantages conferred upon those engaging in 
parallel trade. The precautionary principle has regularly been invoked to justify 
prohibitions even where there are modest health risks to the public22.
The specific and legal economic context of the European prescription 
medicines sector entitles companies to adopt proportionate measures to react 
to the challenges created by parallel trade
The case law of both Community and national courts has increasingly 
recognised that, in light of the economic reality, pharmaceutical companies 
are entitled to appropriate measures responding to the unusual problems 
presented by parallel trade in prescription medicines.
Relevant Community law precedents
Bayer (Adalat)
The first noted EC judicial pronouncement in the modern phase which we 
will describe was Bayer (Adalat) where the Court of First Instance (“CFI”) 
called into question the appropriateness of the Commission stretching the 
19 Para. 4 of the Executive Summary of the Study.
20 Para. 7 of the Executive Summary of the Study.
21 Para. 10 of the Executive Summary of the Study.
22 Communication from the Commission on the Use of the Precautionary Principle, 
COM(2000) 1 final. For more discussion of the precautionary principle, see I. Forrester, “The 
Dangers of Too Much Precaution” [in:] M. Hoskins, W. Robinson (eds.), A True European: 
Essays for Judge David Edward, Oxford/Portland, 2003.
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concept of agreement under Article 81(1) EC for the purpose of attempting 
to bring about market integration in the prescription medicines sector. 
In the 1980s and early 1990s, Bayer pursued a system of limiting supplies 
of its medicinal product Adalat to certain wholesalers in France and Spain. 
Bayer’s system consisted of refusing or reducing orders from “notorious” 
individual wholesalers, with a view to denying to likely exporters supplies they 
would sell in higher-price countries. Thus the policy was intended to reduce 
exports, and this intention was known in the marketplace. Bayer’s posture 
would for many lawyers have appeared risky on the theory that its offers to 
sell were subject to an unwritten but well known term. 
Indeed, these risks were confirmed in January 1996 when, the Commission 
adopted a decision23, considering that there was an unwritten export prohibition 
well known and reluctantly agreed to by wholesalers, which had been part 
of the “continuous commercial relations” between Bayer France and its 
wholesalers since at least 1991, and between Bayer Spain and its wholesalers 
since at least 1989. The Commission asserted there was an agreement between 
Bayer and its wholesalers in that Bayer’s policy was conveyed to the traders 
by many indicators. 
In its judgment, the CFI overturned the Commission’s findings, making 
clear that. 
“the proof of an agreement between undertakings within the meaning of Article 
[81(1)) of the Treaty must be founded upon the direct or indirect finding of the 
existence of the subjective element that characterises the very concept of an 
agreement, that is to say a concurrence of wills between economic operators 
on the implementation of a policy, the pursuit of an objective, or the adoption 
of a given line of conduct on the market, irrespective of the manner in which 
the parties’ intention to behave on the market in accordance with the terms of 
that agreement is expressed (…) The Commission misjudges that concept of the 
concurrence of wills in holding that the continuation of commercial relations with 
the manufacturer when it adopts a new policy, which it implements unilaterally, 
amounts to acquiescence by the wholesalers in that policy, although their de facto 
conduct is clearly contrary to that policy.”24
Paragraph 174 of the judgment goes even further:
“It follows that in the context of that article (Article 81(1), formerly 85(1)), the 
effects on the conduct of an undertaking on competition within the common market 
may be examined only if the existence of an agreement, a decision of an association 
of undertakings or a concerted practice within the meaning of Article [81(1)] of the 
Treaty has already been established (…) It follows that the aim of that provision is 
23 Commission Decision 96/478/EC of 10 January 1996 relating to a proceeding under 
Article [81] of the EC Treaty (Case IV/34.279/F3 – Adalat), OJ [1996] L 201/1.
24 Case T-41/96, Bayer AG v. Commission, [2000] ECR II-3383, para. 173 of the judgment.
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not to eliminate obstacles to intra-Community trade altogether; it is more limited, 
since only obstacles to competition set up as a result of a concurrence of wills 
between at least two parties are prohibited by that provision.”
The CFI also criticised the Commission for stretching the scope of Article 
81(1) EC to bring about market integration in the prescription medicines 
sector. The CFI stated that “under the system of the Treaty it is not open to 
the Commission to attempt to achieve a result, such as the harmonisation of 
prices in the medicinal products market, by enlarging or straining” the scope of 
the competition rules, “especially since that Treaty gives the Commission specific 
means of seeking such harmonisation where it is undisputed that large disparities 
in the prices of medicinal products in the Member States are engendered by 
the differences existing between the state mechanisms for fixing prices and the 
rules for reimbursement, as is the case here”25. The CFI also considered that 
the Commission’s conviction that parallel trade would harmonise prices for 
prescription medicines was “devoid of all foundation”26. 
On appeal, the European Court of Justice (“ECJ”) upheld the CFI’s 
judgment27, ruling more cautiously that an agreement for the purposes of 
Article 81(1) EC “cannot be based on what is only the expression of a unilateral 
policy of one of the contracting parties, which can be put into effect without 
the assistance of others”28. Moreover, the mere concomitant existence of an 
agreement which is in itself neutral, and a measure restricting competition that 
has been imposed unilaterally, does not amount to an agreement prohibited 
by Article 81(1) EC. Consequently, the ECJ held that 
“the mere fact that a measure adopted by a manufacturer, which has the object 
or effect of restricting competition, falls within the context of continuous business 
relations between the manufacturer and its wholesalers is not sufficient for a finding 
that such an agreement exists”29.
The result of Bayer (Adalat) is therefore that pharmaceutical companies 
may reduce the quantities of products they supply to wholesalers, provided 
that they do so unilaterally.
25 Ibid, para. 179.
26 Ibid, para. 181.
27 Joined Cases C-2/01 P and C-3/01 P, Bundesverband der Arzneimittel-Importeure eV and 
Commission v. Bayer AG, [2004] ECR I-23.
28 Ibid, para. 101.
29 Ibid, para. 141.
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GSK Spain
In June 2006, the CFI partially annulled a Commission decision30 that 
had found that Glaxo Wellcome’s, GlaxoSmithKline’s (“GSK”) predecessor, 
General Sales Conditions in Spain, which had been notified to the Commission, 
had the object and the effect of restricting competition and GSK did not 
demonstrate that they contributed to the promotion of technical progress, the 
first necessary condition for exemption under Article 81(3) EC. 
This has been referred to as the “dual pricing” case, but this is a misnomer, 
as in reality GSK only set the price of prescription medicines either not 
reimbursable or not sold in Spain. By contrast, the price for prescription 
medicines which are reimbursable and sold in Spain is set under Article 100 
of Spanish Law 25/1990 (now Article 90 of Spanish Law 29/2006) i.e. by the 
Spanish State and not by GSK.
In its judgment31, the CFI, after noting that competition between 
pharmaceutical companies is based on innovation rather than price32, 
considered that the applicability of Article 81(1) EC cannot depend merely 
on whether an agreement may limit parallel trade but on whether its object or 
effect may limit competition to the detriment of the final consumer33.
“Consequently, while it is accepted that an agreement intended to limit parallel 
trade must in principle be considered to have as its object the restriction of 
competition, that applies in so far as the agreement may be presumed to deprive 
final consumers of those advantages … However, if account is taken of the legal and 
economic context in which GSK’s General Sales Conditions are applied, it cannot 
be presumed that those conditions deprive the final consumers of medicines of 
such advantages. In effect, the wholesalers, whose function, as the Court of Justice 
has held, is to ensure that the retail trade receives supplies with the benefit of 
competition between producers are economic agents operating at an intermediate 
stage of the value chain and may keep the advantage in terms of price which 
parallel trade may entail, in which case that advantage will not be passed on to 
the final consumers”34.
The CFI further noted that price differences between Member States are a 
structural consequence of differences in national regulatory regimes35. 
30 Commission Decision 2001/791/EC of 8 May 2001 (Glaxo Wellcome), OJ [2001] L 
302/1.
31 Case T-168/01, GlaxoSmithKline Services Unlimited v Commission, [2006] ECR II-2969.
32 Ibid, para. 106.
33 Ibid, para. 119.
34 Ibid, paras. 121–122.
35 Ibid, para. 127.
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“[T]he prices of the products in question, which are subject to control by the 
Member States, which fix them directly or indirectly at what they deem to be the 
appropriate level, are determined at structurally different levels in the Community 
and, unlike the prices of other consumer goods to which the Commission referred 
in its written submissions and at the hearing, such as sport items or motor cycles, 
are in any event to a significant extent shielded from the free play of supply and 
demand. That circumstance means that it cannot be presumed that parallel trade 
has an impact on the prices charged to the final consumers of medicines reimbursed 
by the national sickness insurance scheme and thus confers on them an appreciable 
advantage analogous to that which it would confer if those prices were determined 
by the play of supply and demand”36.
The CFI therefore concluded that the price of prescription medicines, 
set by national governments in function of their own choices concerning 
budget, public health, encouragement of investment and other public policy 
considerations lies “structurally outside the play of supply and demand and is 
established at structurally different levels throughout the Community”37. This 
means that, according to the CFI, “[a]s the prices of the medicines concerned 
are to a large extent shielded from the free play of supply and demand owing 
to the applicable regulations and are set or controlled by the public authorities, 
it cannot be taken for granted at the outset that parallel trade tends to reduce 
those prices and thus to increase the welfare of final consumers”38.
Consequently, while an agreement is caught by Article 81(1) EC in so 
far as it may be presumed to harm final consumers, the CFI found that this 
cannot be assumed in relation to the parallel trade of prescription medicines 
in Europe. Rather, the specific context of the prescription medicines sector 
makes it necessary for the Commission to undertake an effects-based analysis 
under Article 81(1) EC.
In that regard, while the CFI ultimately upheld the Commission’s subsidiary 
conclusion that the notified agreement restricted competition by effect39, the 
CFI went on to annul the part of the Commission Decision that rejected GSK’s 
request for an exemption under Article 81(3) EC, because the Commission 
had not appropriately addressed GSK’s “relevant, reliable and credible” 
arguments about the effects of parallel trade on its R&D in perhaps the most 
innovation-driven industry40. 
In so doing, the Court discussed at some length the special characteristics of 
the prescription medicines sector, in particular, the importance of competition 
36 Ibid, paras. 133 and 134.
37 Ibid, para. 141.
38 Ibid, para. 147.
39 Ibid, paras. 165–192.
40 Ibid, para. 263 et seq.
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by innovation. The CFI accepted that parallel trade represented a clear 
reduction of the possibility of pharmaceutical companies to invest more in 
R&D: 
“[P]arallel trade has the effect of reducing [research & development-destined] 
income, to an uncertain but real degree. That practice, which economists know 
as ‘free riding’, is characterised by the fact that the intermediary leaves the role 
which he traditionally plays in the value chain and becomes an arbitrageur and 
thus obtains a greater part of the profit. The legitimacy of that transfer of wealth 
from producer to intermediary is not in itself of interest to competition law, which 
is concerned only with its impact on the welfare of the final consumer. In so far as 
the intermediary participates in intrabrand competition, parallel trade may have a 
pro-competitive effect. In the medicines sector, however, that activity is also seen 
in a special light, since it does not bring any significant added value for the final 
consumer”41.
By contrast, if GSK were allowed to impose certain limitations on parallel 
trade, these would be beneficial for innovation:
“The fact that the profit is retained by the producer will in all likelihood give 
rise to a gain in efficiency by comparison with the situation in which the profit is 
shared with the intermediary, because a rational producer which is able to ensure 
the profitability of its innovations and which operates in a sector characterised by 
healthy competition on innovation has every interest in reinvesting at least a part 
of its surplus profit in innovation”42.
The CFI’s judgment is currently under appeal to the ECJ43.
Syfait
Syfait was the first case in which the ECJ was requested to provide guidance 
on the application of Article 82 EC to unilateral conduct of pharmaceutical 
companies intended to react to parallel trade in prescription medicines. 
The case stemmed from complaints lodged in 2000 and 2001 with the 
Hellenic Competition Commission (“HCC”) by a number of wholesalers, 
alleging that by limiting supplies of certain drugs from its Greek subsidiary, 
GSK was abusing its dominant position, contrary to Article 82 EC. The 
wholesalers in question had been addressing ever-larger orders for prescription 
medicines to GSK Greece, mainly for export, to exploit the price differentials 
in prescription medicines between EU Member States. In 2000 GSK, for one 
41 Ibid, para. 273.
42 Ibid, para. 274.
43 Cases C-501/06 P, GlaxoSmithKline Services Unlimited v Commission; C-513/06 P, 
Commission v GlaxoSmithKline Services Unlimited; C-515/06 P, EAEPC v GlaxoSmithKline 
Services Unlimited; and C-519/06 P, Aseprofar v GlaxoSmithKline Services Unlimited.
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product, had reached the point of supplying seven times Greek demand, yet 
shortages persisted on the Greek market. GSK therefore took the decision 
to suspend supplies to wholesalers for a few weeks to ensure that pharmacy 
supplies were restored. Subsequently, it decided to supply wholesalers with 
quantities corresponding to Greek annual consumption plus a safety margin 
(amounting to 25% of annual Greek consumption).
The HCC referred the case to the ECJ, asking whether the refusal by 
GSK to supply, in unlimited quantities, all the orders placed by wholesalers, 
could constitute an abuse of a dominant position, in light of the fact that 
“parallel trade is particularly profitable for the wholesalers because of the 
different prices, resulting from State intervention, in the Member States of the 
European Union, that is to say by the fact that pure conditions of competition 
do not prevail in the pharmaceuticals market, but a regime which is governed 
to a large extent by State intervention”.
In his Opinion, Advocate General Jacobs considered that a pharmaceutical 
undertaking holding a dominant position does not necessarily abuse that 
position by refusing to meet in full the orders sent to it by wholesalers, even 
if that action will limit parallel trade. In reaching this conclusion, the Advocate 
General referred in particular to: 
• the pervasive and diverse state intervention in the pricing of prescription 
medicines, which is responsible for price differentials between the 
Member States44; 
• the regulation by the Community and the Member States of the distribution 
of prescription medicines, which imposes nationally demarcated 
obligations upon pharmaceutical undertakings and wholesalers to ensure 
the availability of adequate stocks of those products45; 
• the potentially negative consequences of parallel trade for competition, 
the common market, and incentives to innovate, given the economic 
characteristics of the pharmaceutical industry46; and
• the fact that end consumers of prescription medicines may not in all cases 
benefit from parallel trade, and that public authorities in the Member 
States, as the main purchasers of such products, cannot be assumed to 
benefit from lower prices, given that they are themselves responsible for 
fixing prices within their territories47. 
As a result, the Advocate General concluded that because of the specific 
characteristics of the European prescription medicines sector, GSK could not 
44 Opinion of Advocate General Jacobs delivered on 27 October 2004, paras. 77–79.
45 Ibid, paras. 80–82.
46 Ibid, paras. 89–95.
47 Ibid, paras. 96–99.
PARALLEL TRADE IN PRESCRIPTION MEDICINES IN THE EUROPEAN… 23
Vol. 2008, 1(1)
be said to have abused its dominant position48. Furthermore, the Advocate 
General agreed that the parallel trade of prescription medicines does not 
necessarily result in any substantial benefits for ultimate consumers of such 
medicines.
The Grand Chamber of the ECJ never proceeded to a final ruling on the 
merits of that case, since it considered the reference to be inadmissible on 
the grounds that the HCC was not a court or tribunal for the purpose of 
Article 234 EC. Advocate General Jacobs’s Opinion was, however, followed 
by the Hellenic Competition Committee in its decision of 1 September 2006 
on the merits49. It held that GSK had not breached Article 82 EC and more 
specifically it had not abused its dominant position by refusing to supply the 
wholesalers to fuel parallel exports: there was no abuse of dominance, either 
for the October 2000-February 2001 period, when GSK had put in effect a 
system of direct supply of pharmacies and hospitals, or for the period after 
February 2001, when it had resumed supplies to wholesalers on the basis of 
a quota system.
The HCC’s conclusion as to the non-applicability of Article 82 EC was 
based on, inter alia, the following reasons:
“(a) the fact that in the European pharmaceutical sector no strict competition 
conditions apply, due to state interventionism in the price-fixing of pharmaceuticals, 
(b) the percentage by which the quantities supplied by the dominant undertaking 
exceeded national consumption, (c) the effect of parallel trade on the profit 
of the dominant undertaking, (d) the lack of any benefit for the end consumer 
entailed by parallel trade and (e) the overall economic and regulatory context of 
the decision”50.
Lelos
In 2006, the Athens Civil Court of Appeal referred to the ECJ, the same 
questions, based on the same facts, as those already referred by the HCC in 
Syfait.
The case was argued before the Grand Chamber of the ECJ in January 
2008 and Advocate General Colomer delivered his Opinion on 1 April 2008. 
While he agreed with Advocate General Jacobs that there can be no per se 
abuse of Article 82 EC, even where a dominant undertaking has deliberately 
sought to restrict parallel trade, Advocate General Colomer contended that 
such a subjective intention “can often indicate that an anticompetitive outcome 
48 Ibid, paras. 101–102
49 Decision 318/V/2006 of 1 September 2006, accessible at: http://www.epant.gr/Apofaseis.
php3. 
50 Ibid, Section VI.i.b, point 3.
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is being sought51” and may constitute an aggravating factor contributing to the 
presumption that such behaviour was abusive52.
Advocate General Colomer also refused to accept that state intervention 
through price setting or the imposition of public service obligations to ensure 
adequate national supply of patients may constitute an objective justification 
for such an abuse. On the contrary, the Advocate General considered that 
even though “the pharmaceuticals market does not operate under normal 
competitive conditions”, pharmaceutical companies retain a certain margin 
of manoeuvre to negotiate prices with the Member States53 and that the duty 
to ensure adequate supplies to national patients does not justify cutting off 
supplies to “rival” wholesalers, because the needs of patients in Member 
States are not subject to sudden change and statistics for various illnesses are 
reliable, offering companies a degree of predictability which enables them to 
adapt to market demands54. 
Finally, Advocate General Colomer rejected as “misleading” the contention 
that the protection of a pharmaceutical company’s legitimate business 
interests may justify its conduct and that there is any causal link between 
the losses sustained by pharmaceutical companies due to parallel trade and 
their investment in R&D. In his words, these arguments were “aimed only at 
seducing public opinion, which is sensitised to the vital importance of R&D 
for competitiveness, by shifting the focus from business rivalry to research 
policy.”55 The Advocate General felt that GSK had not indicated any positive 
effects resulting from its refusal to supply prescription medicines to Greek 
wholesalers56.
The ECJ’s judgment was therefore awaited with particular interest as the 
Court had before it contrasting Opinions from two of its Advocate Generals 
on the same legal issue.
On the one hand, the ECJ considered some of the policy arguments which 
the pharmaceutical industry has traditionally put forward in order to justify 
imposing limits on parallel trade.
First, the judgment confirms that a pharmaceutical company is abusing 
its dominant position if it refuses to meet ordinary orders by wholesalers of 
prescription medicines in order to prevent parallel exports. This principle is 
not new, although it was extensively commented upon57.
51 Lelos, Opinion of 1 April 2008, para. 49.
52 Ibid, paras. 50–51.
53 Ibid, para. 93.
54 Ibid, para. 96.
55 Ibid, para. 113.
56 Ibid, para. 118.
57 Judgment in Joined Cases C-468/06-478/06, para. 66.
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Second, the ECJ found that parallel trade does create some benefits both 
by exerting “pressure on prices” and opening up an alternative source of 
supply for purchasers58.
Third, the ECJ doubted that state intervention in the prescription medicines 
sector means that pharmaceutical companies have no influence upon the level 
at which prices are set and that such intervention entirely removes the prices 
of prescription medicines from the forces of supply and demand59.
Fourth, the Court considered that “where a medicine is protected by a patent 
which confers a temporary monopoly on its holder, the price competition 
which may exist between a producer and its distributors, or between parallel 
traders and national distributors, is, until the expiry of that patent, the only 
form of competition which can be envisaged”60.
Fifth, in situations where parallel exports lead to shortages in the Member 
State of export, it is for the competent health authorities of that Member State, 
and not for dominant pharmaceutical companies, to take the appropriate and 
proportionate steps to address such shortages61.
On the other, the judgment contains important and welcome statements 
confirming that pharmaceutical companies are entitled to adopt measures 
responding to the unusual problems presented by parallel trade in prescription 
medicines. 
First, the Court accepted that the “price differences between Member 
States for certain medicines are … the result of the different levels at which 
the prices and/or the scales to be applied to those medicines are fixed” by 
the State and not due to other parameters, such as currency fluctuations62, 
something which the European Commission and parallel traders had not been 
willing to concede.
Second, the Court rejected the argument that once a pharmaceutical 
company decides to put its product on the market in a certain Member State 
at the price set by the State, it can no longer take any measures to protect its 
interests: 
“In the light of the Treaty objectives to protect consumers by means of undistorted 
competition and the integration of national markets, the Community rules on 
competition are also incapable of being interpreted in such a way that, in order 
to defend its own commercial interests, the only choice left for a pharmaceuticals 
company in a dominant position is not to place its medicines on the market at all 
58 Ibid, paras. 53–56.
59 Ibid, paras. 61–63.
60 Ibid, para. 64
61 Ibid, para. 75.
62 Ibid, para. 59.
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in a Member State where the prices of those products are set at a relatively low 
level”63. 
Finally, the Court made clear that a dominant pharmaceutical company 
must be in a position to take steps that are reasonable and in proportion to 
the need to protect its own commercial interests: 
“although a pharmaceuticals company in a dominant position, in a Member State 
where prices are relatively low, cannot be allowed to cease to honour the ordinary 
orders of an existing customer for the sole reason that that customer, in addition to 
supplying the market in that Member State, exports part of the quantities ordered 
to other Member States with higher prices, it is none the less permissible for that 
company to counter in a reasonable and proportionate way the threat to its own 
commercial interests potentially posed by the activities of wholesalers which wish 
to be supplied in one Member State with significant quantities of products that are 
essentially destined for parallel export”64.
In particular, a dominant pharmaceutical company must able to protect 
its own commercial interests when confronted with orders that are out of the 
ordinary, in light of both the previous business relations and the requirements 
of the market in the relevant Member State:
 “a producer of pharmaceutical products must be in a position to protect its own 
commercial interests if it is confronted with orders that are out of the ordinary 
in terms of quantity. Such could be the case, in a given Member State, if certain 
wholesalers order from that producer medicines in quantities which are out of all 
proportion to those previously sold by the same wholesalers to meet the needs of 
the market in that Member State”65. 
Relevant national decisions and academic literature also support the proposition 
that the pharmaceutical industry is entitled to take reasonable and proportionate 
steps to respond to parallel trade
National courts and competition authorities across the EU have also 
concluded that the pharmaceutical industry is entitled to take reasonable and 
proportionate steps to respond to parallel trade.
In France, the Competition Council has found that “the correct application 
of competition law requires to take into account completely the existence 
of price regulation”66 and that accordingly “we fail to see what justification 
63 Ibid, para. 68.
64 Ibid, para. 71.
65 Ibid, para. 76.
66 Case 05-D-72 of 20 December 2005 relative à des pratiques mises en oeuvre par divers 
laboratoires dans le secteur des exportations parallèles de médicaments, para. 269, authors’ own 
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would allow an economic operator to impose on a producer who does not 
dispose of the freedom to fix the price of its products intended to be used 
on a territory, to apply in a general way the same terms of sale for products 
intended exclusively for other territories where the conditions of market are 
different”67. 
This decision was confirmed by the Paris Court of Appeal, which found that 
“in light of the particular situation that prevails in France, it is not excessive 
for a pharmaceutical company to defend its commercial interests by refusing 
to deliver its products set at a fixed price administered to an operator who 
sells no product on the national market for which the price has been fixed and 
who seeks to obtain this product only on condition that the price fixed by the 
authorities in view of its use on in the national territory allows it to resell the 
product) on a foreign market with profit”68.
In Spain, the Competition Tribunal69 has held that it is not right to say that 
“pharmaceutical companies enjoy independence in freely determining their 
prices, because Spanish legislation is governed by a system of price intervention 
of pharmaceuticals, which must be authorised by the Administration in all stages 
of their marketing”. Moreover, a judgment of Spain’s second highest court 
(the Audiencia Nacional), has declared that “parallel exports mainly benefit 
wholesalers, who obtain disproportionate, unexpected and exceptionally high 
profits (“wind-fall profits”). In other terms, parallel exports do not constitute 
any direct benefit for consumers that pay the same price for the pharmaceutical 
product, whether it originates or not from a parallel import”70.
translation from the French original: “la bonne application du droit de la concurrence nécessite 
de prendre pleinement en compte l’existence d’une réglementation des prix”.
67 Ibid, para. 267, authors’ own translation from the French original: “on ne voit pas quelle 
justification permettrait à un opérateur économique d’imposer à un producteur qui ne dispose pas 
de la liberté de fixer ses prix pour les produits destinés à être utilisés sur un territoire, d’appliquer 
d’une manière générale les mêmes conditions de vente pour des produits destinés exclusivement à 
d’autres territoires où les conditions de marché sont différentes”.
68 1st Chamber, Section H, Judgment of 23 January 2007, authors’ own translation from the 
French original: “au vu de la situation particulière que prévaut en France (…) il n’est pas abusif 
pour un laboratoire de défendre ses intérêts commerciaux en refusant de livrer ses produits à un 
prix administré à un opérateur qui ne vend aucun produit sur le marché national pour lequel la 
réglementation du prix a été élaborée et qui ne recherche ce produit qu’à la condition que le prix 
fixé par les pouvoirs publics en vue d’un usage sur le territoire national lui permette de le revendre 
sur un marché étranger avec profit”.
69 Resolution of 5 December 2001, Expte. R 488/01, Laboratorios Farmacéuticos. 
70 Judgment of the Audiencia Nacional of 26.1.2005 (appeal nº 364/2001), authors’ own 
translation from the Spanish original: “las exportaciones paralelas benefician principalmente a los 
mayoristas, que obtienen ganancias desproporcionadas, inesperadas y excepcionalmente elevadas 
(“wind-fall profits”). Es decir, las exportaciones paralelas no representan ningún beneficio directo 
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In Greece, a series of decisions and judgments have also made similar 
findings.
First, as noted above, the HCC, in the aftermath of the Syfait preliminary 
reference, duly adopted Advocate General Jacobs’s findings, and concluded 
that there was no Article 82 EC violation and that GSK had not abused its 
dominant position by introducing a quota system for its supply of prescription 
medicines to Greek wholesalers.
Second, the Athens Court of Appeals reversed the only ruling out of 17 cases, 
which had found that GSK had abused its dominant position under both Greek 
and EC competition law by refusing to supply Pharmacon D. Politis, a local 
wholesaler, with certain prescription drugs destined for export to the United 
Kingdom71. The Court of Appeals held that GSK’s conduct was not abusive and 
placed emphasis on the fact that the Greek State set the price for all prescription 
drugs at the lowest level in the EU. In the Court’s view, no negative effects on 
the Greek market were proven and parallel trade brought no benefit to final 
consumers. At the same time, according to the Court, GSK had to protect its 
legitimate interests. Prices were set only for Greece, in the Court’s words.
Third, and in a separate development, the Greek Supreme Court, (the 
“Areios Pagos”) handed down its judgment in the Servier72 case, in which it 
concluded that Servier’s quota schemes were not a violation of Greek/EC 
competition law. The Supreme Court noted inter alia the profits that the 
wholesalers were making due to the fact that the Greek State had set the 
prices of prescription medicines at the lowest rate in the EU, that there were 
some shortages in Greece due to the soaring parallel exports and that even 
the reduced quotas supplied far exceeded Greek demand. The Supreme Court 
concluded that “the refusal to supply by [Servier] was neither unreasonable, 
nor abusive, nor contrary to the good morals”. Servier’s quota system 
“was not intended to restrict competition but rather to protect its economic 
interests, which were encroached upon by certain wholesalers through their parallel 
exports, and thus to secure the satisfaction of the local needs of the medicines’ 
import countries, which is not in the least unreasonable or illegal. If this were 
considered unreasonable, it would be possible for [Servier] to be required to supply 
unlimited quantities of its products to the appellants, at the free will of the latter, 
thus essentially supplying all EU-destined products through them, which is of 
course unacceptable”.
para los consumidores que pagan el mismo precio por el producto farmacéutico, proceda o no de 
una importación paralela”.
71 Judgment No 7770/2007 of 22 November 2007. This case is part of the Lelos line of cases. 
However, it was never referred because it was procedurally separate. There were also five more 
cases in which GSK prevailed at first instance and which the wholesalers did not appeal.
72 Judgment No 1334/2007 of 11 June 2007.
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Finally, there is an growing body of academic literature which follows the 
logic and approves of the Bayer (Adalat), GSK Services Unlimited and now 
Lelos judgments73.
Conclusions
In light of the economic reality, which is increasingly confirmed by relevant 
judicial authorities, we submit that hindering parallel trade in prescription 
medicines does not damage patients and national health budgets.
It is therefore to be welcomed that both Community and national case law 
has confirmed that pharmaceutical companies are entitled to adopt measures 
responding to – but not prohibiting or eliminating – parallel trade, and such 
73 Compare F. Jenny “Pharmaceuticals, Competition and Free Movement of Goods” [in:] 
EU Competition Law and Policy, Developments and Priorities, Hellenic Competition Committee 
(ed.), Athens Conference, April 19th 2002, Athens, Nomiki Vivliothiki, p. 83–84; P. Rey, J.S. 
Venit, “Parallel Trade and Pharmaceuticals: A Policy in Search of Itself” (2004) 29 E.L.R. 153; 
Dawes A., “Neither Head nor Tail: The Confused Application of EC Competition Law to the 
Pharmaceutical Sector” (2006) 27 E.C.L.R. 269; V. Korah, Intellectual Property Rights and the EC 
Competition Rules, Oxford/Portland, 2006, p. 149; D. Chalmers, C. Hadjiemmanuil, G. Monti, 
A.Tomkins, European Union Law, Cambridge 2006, p. 999–1000; E. Dieny, “Appréciation au 
regard du droit communautaire de la concurrence d’un accord visant à réduire le commerce 
parallèle des médicaments” (2006) JCP La Semaine Juridique 2153; R. Eccles, “Parallel Exports 
in the Pharmaceuticals Sector: Take Nothing for Granted” (2007) 28 E.C.L.R. 138–142; 
H. Calvet, “Commerce parallèle et droit européen : La fin d’un dogme ?” (2007) 10 Revue 
Lamy de la Concurrence 138; L. Souto Soubrier “The Concept of an Agreement and Beyond: 
How to Block Parallel Imports of Pharmaceuticals to Protect the Heart of Competition” [in:] 
G. Amato, C.D., p. 81; V. Korah, “Judgment of the Court of First Instance in GlaxoSmithKline” 
(2007) 6 Competition Law Journal, p. 101; W-H. Roth, “Möglichkeiten und Grenzen eines 
einheitlichen Binnenmarktes für Arzneimittel” [in:] J. Schwarze, U. Becker (eds.), Arzneimittel im 
Europäischen Binnenmarkt, Europarecht Beiheft 2/2007, Baden-Baden 2007, p. 37–42; P. Behrens, 
“Parallelhandelsbeschränkungen und Konsumentenwohlfahrt – Zur neueren Rechtsrechung 
von EuG und EuGH” (2008) 6 Zeitschrift für Wettbewerbsrecht 20; V. Junod, “An End to 
Parallel Imports of Medicines? Comments on the Judgment of the Court of First Instance in 
GlaxoWellcome” (2007) 30 World Competition 291; C. Köning, C. Engelmann, “Parallel Trade 
Restrictions in the Pharmaceutical Sector on the Test Stand of Article 82 EC: Commentary 
on the Opinion on Advocate General Jacobs in the Case Syfait/Glaxosmithkline”, (2005) 25 
E.C.L.R. 465; R. Smits, “On Parallel Trade and Preliminary Issues – A Healthy Approach to 
Competition Law Enforcement?” (2006) 33 Legal Issues of European Integration 61. See also 
A. Nikpay, L. Kjølbye and J. Faull [in:] J. Faull, A. Nikpay (eds.), The EC Law of Competition, 
Oxford, 2007, p. 260, viewing the O2, Österreichische Postsparkasse and GlaxoSmithKline 
Services Unlimited judgments of the CFI broadly in line with the general approach set out in 
the Commission’s Article 81(3) EC Guidelines, which focus on consumer welfare (Commission 
Notice – Guidelines on the Application of Article 81(3) of the Treaty, OJ [2004] C 101/97).
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measures are not contrary to the EC competition rules. Parallel traders had 
previously been free-riding on case law which referred to sectors and cases 
that bore no relation to the special features of the European prescription 
medicines sector. To the extent there is an assumption that parallel trade in 
Europe safeguards intra-brand competition, the recent case law does not call 
this assumption into question: on the contrary, it confirms it, while noting that 
this assumption is inapplicable to the prescription medicines sector in Europe 
precisely because of that sector’s very specific features. 
It is therefore to be hoped that the long-running obsession of European 
competition law with parallel trade in prescription medicines may (at last) be 
coming to an end. 
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